Evidence map›Paper›PMID 35422810›Full record

ArticleFrontiers in immunology2022

Alterations of Urinary Microbial Metabolites and Immune Indexes Linked With COVID-19 Infection and Prognosis.

Yixian Jing, Jing Wang, Haiyan Zhang, Kun Yang, Jungang Li, Ting Zhao, Jiaxiu Liu, Jing Wu, Yaokai Chen

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yixian JingDivision of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.
Jing WangDepartment of Clinical Laboratory, Chongqing Public Health Medical Center, Chongqing, China.
Haiyan ZhangDepartment of Clinical Laboratory, Chongqing Public Health Medical Center, Chongqing, China.
Kun YangDepartment of Clinical Laboratory, Chongqing Public Health Medical Center, Chongqing, China.
Jungang LiDepartment of Clinical Laboratory, Chongqing Public Health Medical Center, Chongqing, China.
Ting ZhaoDivision of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.
Jiaxiu LiuDepartment of Clinical Laboratory, Chongqing Public Health Medical Center, Chongqing, China.
Jing WuDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yaokai ChenDivision of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.
Chongqing Public Health Medical Center · CNFirst Affiliated Hospital of Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) has evolved into an established global pandemic. Metabolomic studies in COVID-19 patients is worth exploring for further available screening methods. In our study, we recruited a study cohort of 350 subjects comprising 248 COVID-19 patients (161 non-severe cases, 60 asymptomatic cases, and 27 severe cases) and 102 healthy controls (HCs), and herein present data with respect to their demographic features, urinary metabolome, immunological indices, and follow-up health status. We found that COVID-19 resulted in alterations of 39 urinary, mainly microbial, metabolites. Using random forest analysis, a simplified marker panel including three microbial metabolites (oxoglutaric acid, indoxyl, and phenylacetamide) was constructed (AUC=0.963, 95% CI, 0.930-0.983), which exhibited higher diagnostic performance than immune feature-based panels between COVID-19 and HC groups (

Indexed as

COVID-19CD8-Positive T-LymphocytesHumansMetabolomePrognosisSARS-CoV-2COVID-19diagnostic performancehigh-risk sequelaehigh-risk sequelae COVID-19immune dysfunctionurinary microbial metabolites

Identifiers

PMID35422810
PMCPMC9001849
OpenAlexW4220787921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.